{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T19:37:29Z","timestamp":1720553849108},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1053\/j.seminoncol.2005.06.017","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"16-23","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S5","title":["Treatment Strategies and Issues in Low\/Intermediate-1\u2013Risk Myelodysplastic Syndrome (MDS) Patients"],"prefix":"10.1053","volume":"32","author":[{"given":"David T.","family":"Bowen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2005.06.017_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1365-2141.1998.00708.x","article-title":"Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes","volume":"101","author":"Parker","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.thj.6200335","article-title":"Myelodysplastic syndromes","volume":"5","author":"Hofmann","year":"2004","journal-title":"Hematol J"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib3","first-page":"122","article-title":"Approach to anemia associated with myelodysplastic syndromes","volume":"2","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998;91:1100]","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib5","first-page":"141","article-title":"Treatment of adult myelodysplastic syndromes","volume":"70","author":"Hellstr\u00f6m-Lindberg","year":"1999","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib6","first-page":"910","article-title":"A patient-oriented approach to treatment of myelodysplastic syndromes","volume":"83","author":"Cazzola","year":"1998","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.seminhematol.2004.02.002","article-title":"Myelodysplastic syndromes: From pathogenesis and prognosis to treatment","volume":"41","author":"Fenaux","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1634\/theoncologist.7-suppl_1-39","article-title":"New approaches to the treatment of myelodysplasia","volume":"7","author":"List","year":"2002","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib10","unstructured":"National Comprehensive Cancer Network (NCCN) Myelodysplastic Panel Members: NCCN practice guidelines: Myelodysplastic syndromes v1. 2005. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/mds.pdf. (accessed February 16, 2005)"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib11","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life","volume":"120","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.leu.2401618","article-title":"A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies","volume":"14","author":"Rosenfeld","year":"2000","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0145-2126(96)00008-2","article-title":"Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes","volume":"20","author":"Shetty","year":"1996","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib16","first-page":"184","article-title":"The role of angiogenesis in the biology and therapy of myelodysplastic syndromes","volume":"3","author":"Aguayo","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0959-8049(02)00628-7","article-title":"Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa","volume":"39","author":"Patrick","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, control trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib20","doi-asserted-by":"crossref","unstructured":"Garypidou V, Verrou E, Vakalopoulou S, et al: Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 123:958-2003","DOI":"10.1046\/j.1365-2141.2003.04697.x"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2141.2003.04435.x","article-title":"Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes","volume":"122","author":"Musto","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s002280100324","article-title":"Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly","volume":"57","author":"Cheung","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2141.2002.03583.x","article-title":"Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients","volume":"118","author":"Terpos","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1046\/j.1365-2141.1998.00920.x","article-title":"Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor V\u03b2 profiles","volume":"102","author":"Molldrem","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7326\/0003-4819-137-3-200208060-00007","article-title":"Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes","volume":"137","author":"Molldrem","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","article-title":"A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia","volume":"120","author":"Killick","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib27","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib28","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","article-title":"Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients","volume":"18","author":"Wijermans","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14656566.5.3.613","article-title":"Arsenic trioxide for the treatment of myelodysplastic syndromes","volume":"5","author":"Vey","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib31","first-page":"204a","article-title":"CERA (continuous erythropoiesis receptor activator) demonstrates does-dependent activity and is well tolerated in phase 1 multiple ascending dose studies","volume":"102","author":"Dougherty","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00062752-200205000-00009","article-title":"Applications of darbepoietin-\u03b1, a novel erythropoiesis-stimulating protein, in oncology","volume":"9","author":"Smith","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib33","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","article-title":"Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid","volume":"104","author":"Kuendgen","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.leukres.2003.08.007","article-title":"Thalidomide therapy for myelodysplastic syndromes: Current status and future perspectives","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","article-title":"Thalidomide for the treatment of patients with myelodysplastic syndromes","volume":"16","author":"Strupp","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.06.017_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775405002575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775405002575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:06:34Z","timestamp":1586523994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775405002575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":38,"alternative-id":["S0093775405002575"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2005.06.017","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}